English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Jaguar8 commented on a stock · Nov 25, 2024 22:03

NEWS

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNS Pharmaceuticals (NASDAQ:CNSP)presented updated results from its ongoing pivotal study comparing Berubicin versus Lomustine in adult patients with recurrent glioblastoma (GBM). The study has enrolled 239 patients, with comparable demographics between treatment arms. Key findingsshow higher study completion rates in the Berubicin arm (84.7% vs 78.9%) and lower withdrawal rates (11.0% vs 19.7%) compared to Lomustine. Safety profiles were similar between arms, with Berubicin showing slightly higher rates of anemia and neutropenia, while Lomustine had more thrombocytopenia cases. The company expects to report primary analysis data in the first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
+0
Translate
Report
5531 Views
Comment
Sign in to post a comment
    avatar
    Jaguar8
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8195
    Followers
    50
    Following
    93K
    Visitors
    Follow
    Heat List
    US
    SymbolMini ChartPrice
    TSLA
    Tesla
    -- 355.840
    NVDA
    NVIDIA
    -- 138.850
    INTC
    Intel
    -- 23.600
    BABA
    Alibaba
    -- 124.730
    GRAB
    Grab Holdings
    -- 4.900
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
    MicroStrategy Q4 2024 earnings conference call
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.